Moxifloxacin (BAY12-8039)
Sponsors
Bayer
Conditions
Healthy
Phase 1
Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects
CompletedNCT00310596
Start: 2004-01-31End: 2004-03-31Updated: 2014-12-30
Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults
CompletedNCT01073891
Start: 2010-05-31End: 2011-01-31Updated: 2015-07-01